loading page

Sofosbuvir for Covid-19 infection: A Potential Candidate
  • Rohit Gupta,
  • Ajit Bhadoria,
  • Puneet Dhamija
Rohit Gupta
All India Institute of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Ajit Bhadoria
Author Profile
Puneet Dhamija
All India Institute of Medical Sciences
Author Profile


SARS COV-2 and its related disease COVID 19 has led to a major global pandemic and in absence of no known effective therapeutic agents against it, virus is having a free run. Sequence analyses, homology modelling and docking have suggested potential drugs which can be used against this virus. Sofosubivir is a direct-acting antiviral agent with NS5B RNA-dependent RNA polymerase (RdRp) inhibitory activity used in management of Hepatitis-C infection. This drug has potential role in managing this viral disease. Safety and efficacy of this drug is already established in patients of Hepatitis-C where it is given for long periods of time. Favourable pharmacokinetic profile of this drug also favors it use in this infection. This report summarises information available which can be explored further in clinical trials.
2020Published in Indian Journal of Pharmacology volume 52 issue 3 on pages 232. 10.4103/ijp.IJP_675_20